Friday, 16 October 2026European Markets

ELIS And RELX Have A High Dividend Yield And Return On Equity In The Specialty Business Services Industry.

Loading stream...

(vianews) - elis (elis.pa) is among this list of stock assets with the highest dividend rate and return on equity on the specialty business services industry.

financial asset price forward dividend yield return on equity
elis (elis.pa) €21.06 2.07% 7.85%
relx (ren.as) €38.54 1.73% 49.72%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. elis (elis.pa)

2.07% forward dividend yield and 7.85% return on equity

elis sa provides flat linen, workwear, and hygiene and well-being solutions in france, central europe, scandinavia, eastern europe, the united kingdom, ireland, latin america, southern europe, and internationally. the company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. it provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. in addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. it serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. the company was founded in 1883 and is headquartered in saint-cloud, france.

earnings per share

as for profitability, elis has a trailing twelve months eps of €1.06.

pe ratio

elis has a trailing twelve months price to earnings ratio of 19.87. meaning, the purchaser of the share is investing €19.87 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.85%.

more news about elis.

2. relx (ren.as)

1.73% forward dividend yield and 49.72% return on equity

relx plc, together with its subsidiaries, provides information-based analytics and decision tools for professional and business customers in north america, europe, and internationally. it operates through four segments: risk; scientific, technical & medical; legal; and exhibitions. the risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk. the scientific, technical & medical segment provides information and data sets that help researchers and healthcare professionals to advance science and health outcomes. the legal segment provides legal, regulatory, and business information and analytics that help customers in decision-making, as well as increases the productivity. the exhibitions segment is involved in the business that combines face-to-face with data and digital tools to help customers learn about markets, source products, and complete transactions. the company was formerly known as reed elsevier plc and changed its name to relx plc in july 2015. relx plc was incorporated in 1903 and is headquartered in london, the united kingdom.

earnings per share

as for profitability, relx has a trailing twelve months eps of €1.09.

pe ratio

relx has a trailing twelve months price to earnings ratio of 35.36. meaning, the purchaser of the share is investing €35.36 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 49.72%.

revenue growth

year-on-year quarterly revenue growth grew by 1.7%, now sitting on 9.16b for the twelve trailing months.

volume

today's last reported volume for relx is 227546 which is 65.54% below its average volume of 660331.

more news about relx.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com